Results - Announcements
Senores Pharmaceuticals Ltd share price retreated by 7.97% to Rs 1218.55. The Company's net profit soared by 20.20% to Rs 36.6 crore, while revenue from operations improved marginally 6.73% to Rs 192.33 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.44%. It has marginally improved by 5.74% over last one week and crept higher by 0.60% in last one month while the market capitalization of Senores Pharmaceuticals Ltd has inched up 0.38% and 6.37% in the same period respectively.
Profit before tax (PBT) of Senores Pharmaceuticals Ltd stood at Rs 47.58 crore in Q3 FY26, rallying 17.08% year-on-year, and jumping 20.58% quarter-on-quarter. EBITDA came in at Rs 49 crore, expanding by 71.19% YoY and declining 4.38% sequentially.
Total expenses grew marginally by 6.25% to Rs 144.92 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 28.39 crore, marginally falling by 8.86% YoY, while employee benefits expense was at Rs 32.41 crore, registering a growth of 8.36% YoY.
For the TTM ended FY26, revenue from operations surged 85.65% to Rs 398.25 crore, while net profit jumped 78.36% to Rs 58.34 crore, compared to previous TTM. EBITDA surged by 4460% to Rs 70.44 crore, and PBT witnessed a strong rise of 182.85% to Rs 70.57 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 45.92 crore in FY26, as against Rs 25.7 crore in FY25.
Senores Pharmaceuticals Ltd rallied 57.29% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 12.76% during the same period.